Dr. Christine McLaughlin, MD
What this data tells you about Dr. McLaughlin
Dr. Christine McLaughlin is an endocrinology specialist in Cambridge, MA, with 21 years of NPI registration. Based on federal Medicare data, Dr. McLaughlin performed 9,749 Medicare services in 2023. These records do not provide a deduplicated patient total.
Between the years covered by Open Payments, Dr. McLaughlin received a total of $5,393 from 26 pharmaceutical and/or device companies across 230 payment records. A record can group multiple payments. These transfers are publicly reported through CMS Open Payments. Disclosure alone does not establish their effect on care. A reliable breakdown by payment category is not available in this snapshot. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. McLaughlin is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
Medicare Practice Summary — 2023
Medicare Utilization ↗Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Denosumab injection (Prolia/Xgeva) | 7,800 | $18 | $27 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
814 | $100 | $332 |
| Blood glucose test using hand-held instrument A test that measures the level of sugar in the blood using a portable device. The result helps monitor blood glucose levels. |
298 | $3 | $8 |
| Hemoglobin A1c test (diabetes monitoring) A blood test that measures your average blood sugar levels over the past two to three months. |
286 | $9 | $27 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
145 | $13 | $52 |
| Continuous glucose monitoring with interpretation This procedure involves monitoring blood sugar levels in tissue fluid using a sensor placed under the skin, along with the interpretation and reporting of the results. |
87 | $27 | $99 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
78 | $132 | $391 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
66 | $74 | $229 |
| Diabetes self-management training, individual Individualized education and training for managing diabetes, billed per 30-minute session. |
66 | $45 | $143 |
| Ultrasound-guided fine needle aspiration biopsy, first lesion A biopsy procedure where a thin needle is used to collect tissue samples from a growth, guided by ultrasound imaging. This code applies to the first lesion or mass sampled during the session. |
65 | $120 | $296 |
| Blood draw (venipuncture) Insertion of a needle into a vein to collect a blood sample. |
32 | $6 | $6 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
12 | $116 | $443 |
Industry Payment Transparency
Open Payments through 2024 ↗Payment categories are unavailable while the source breakdown is being rebuilt. Company and year totals do not identify how much belongs to each category.
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
Payments by company (2024)
All-time payments by company (2018-2024) ›
Associated products mentioned in payments ›
Geographic Context
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | NPPES snapshot; verify current record |
| Medicare Enrollment | ✓ PECOS | PECOS snapshot |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not included | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. McLaughlin is a mixed practice specialist, with above-average Medicare volume (top 4% in MA), with 21 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. McLaughlin experienced with denosumab injection (prolia/xgeva)?
Does Dr. McLaughlin receive payments from pharmaceutical companies?
How do Dr. McLaughlin's costs compare to other endocrinologists in Cambridge?
What does Data Coverage mean?
Is this data up to date?
Explore related providers
This page combines public CMS records with calculated summaries and explanatory procedure labels. These transformations are not verbatim federal records. Sources: NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology